Members of a task force in Minnesota are making progress toward issuing a report on how the state might regulate psychedelics, including psilocybin, MDMA and LSD. The group earlier this month held preliminary votes on certain policy recommendations—including on eliminating penalties for personal possession and regulating clinical access to some entheogens—with more votes expected at its next meeting in October.

Two recommendations that are already approved by the body are the creation of a state-regulated clinical psilocybin program and the appropriation of research dollars to study the therapeutic use of psilocybin, MDMA and LSD. It will be up to lawmakers, however, to introduce and pass any psychedelics-related legislation to formally enact the suggestions.